Australia's drug regulator has put unapproved peptides on a formal enforcement list. Four of the five compounds it singled out have almost no controlled human evidence behind them. The fifth is a late-stage obesity drug that has not finished its trials.
The Therapeutic Goods Administration (TGA) made unapproved peptide products a compliance priority for 2026 and 2027, meaning the agency will actively pursue the people importing, compounding, advertising, and selling them. In its announcement ↗, the TGA said these products are not on the Australian Register of Therapeutic Goods and have not been assessed for safety, quality, or effectiveness. The agency's head, Anthony Lawler, tied the move to rising supply, saying evidence of "potential risk to consumers" had grown as availability spread.
What enforcement looks like
The TGA listed infringement notices, product seizures, import interventions, and civil or criminal penalties as the tools it can use. This is not theoretical. In an eight-month joint operation with the Australian Border Force and Victoria Police, authorities seized more than 2 million Australian dollars ↗ worth of peptides, performance-enhancing drugs, and illicit steroids, and arrested three people in Victoria. The Border Force investigation started in August 2025 after agents intercepted 640 vials of performance- and image-enhancing drugs moving through air cargo.
The list is the interesting part
Four of the five named peptides are research-grade compounds sold ahead of the evidence. BPC-157 ↗, a synthetic fragment marketed for healing, rests on animal studies and a single twelve-patient case series. TB-500 ↗ (a thymosin beta-4 fragment) and CJC-1295 ↗, a growth-hormone releaser, sit in the same grey market of injectables sold for recovery and muscle with no approval behind them. GHK-Cu ↗ is a copper-binding skin peptide that is legitimate in topical cosmetics but not as an injectable. None of the four has the kind of randomized human trial data that gets a drug registered.
Then there is retatrutide ↗. It does not belong in that group. It is Eli Lilly's triple-receptor obesity drug, in Phase 3 right now, the one that has posted some of the largest weight-loss figures the field has seen. It lands on the watchlist not because the science is thin but because demand has run ahead of approval, and a grey market formed to supply a drug people cannot yet get prescribed. The TGA is treating a supply problem, not a weak molecule.
That mix is what makes the action worth reading as a signal rather than a routine crackdown. The same enforcement net now covers compounds that may never clear a trial and one that very likely will. The regulatory status and the scientific status are moving on separate tracks, and lumping all five under one heading can blur that. A buyer who reads "unapproved" as "unproven" gets BPC-157 right and retatrutide wrong.
peptidemodel hosts a card for each of the five, tagged with what is actually known about its evidence. The TGA list and the evidence base are not the same map. ↯